A Quantitative Proteomic Analysis Uncovers the Relevance of CUL3 in Bladder Cancer Aggressiveness

PLoS ONE

Volumn 8, Issue 1, 2013, Pages

  Grau, Laura ^a   Luque Garcia, Jose L ^b   González Peramato, Pilar ^c   Theodorescu, Dan ^d   Palou, Joan ^e   Fernandez Gomez, Jesus M ^f   Sánchez Carbayo, Marta ^a  

^a Centro Nacional de Investigaciones Oncológicas   (Spain)

^b UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^c HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^d UNIVERSITY OF VIRGINIA   (United States)

^e FUNDACIÓ PUIGVERT   (Spain)

^f HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CAVEOLIN; CYTOSKELETON PROTEIN; EZRIN; FILAMIN; MESSENGER RNA; MOESIN; OLIGONUCLEOTIDE; SMALL INTERFERING RNA;

AGED; ARTICLE; BLADDER CANCER; CANCER GROWTH; CANCER STAGING; CELL MIGRATION; CELL PROLIFERATION; DISEASE SPECIFIC SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; ISOTOPE LABELING; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; MOLECULAR MECHANICS; NUCLEOTIDE SEQUENCE; OUTCOME ASSESSMENT; PHENOTYPE; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN TARGETING; PROTEOMICS; QUANTITATIVE ANALYSIS; UBIQUITINATION; VALIDATION PROCESS;

CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CHROMATOGRAPHY, LIQUID; CULLIN PROTEINS; CYTOSKELETAL PROTEINS; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMANS; ISOTOPE LABELING; LYMPHATIC METASTASIS; NEOPLASM INVASIVENESS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; PROTEOMICS; SIGNAL TRANSDUCTION; TANDEM MASS SPECTROMETRY; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 84872176059     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0053328     Document Type: Article

References (50)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, et al. (2009) Cancer statistics 2009. CA Cancer J Clin 59: 225-49.
2. Sánchez-Carbayo M, Cordon-Cardó C (2007) Molecular alterations associated with bladder cancer progression. Semin Oncol. 34, 75-84.
3. Smith SC, Theodorescu D, (2009) The Ral GTPase pathway in metastatic bladder cancer: key mediator and therapeutic target. Urol Oncol 27: 42-7.
4. Apolo AB, Milowsky M, Bajorin DF, (2009) Clinical states model for biomarkers in bladder cancer. Future Oncol 5: 977-92.
5. Gildea JJ, Golden WL, Harding MA, Theodorescu D, (2000) Genetic and phenotypic changes associated with the acquisition of tumorigenicity in human bladder cancer. Genes Chromosomes Cancer 27: 252-263.
6. Seraj MJ, Harding MA, Gildea JJ, Welch DR, Theodorescu D, (2001) The relationship of BRMS1 and RhoGDI2 gene expression to metastatic potential in lineage related human bladder cancer cell lines. Clin. Experim. Metastasis 18: 519-525.
7. Harding MA, Arden KC, Gildea JW, Gildea JJ, Perlman EJ, et al. (2002) Functional genomic comparison of lineage-related human bladder cancer cell lines with differing tumorigenic and metastatic potentials by spectral karyotyping, comparative genomic hybridization, and a novel method of positional expression profiling. Cancer Res 62: 6981-6989.
8. Gildea JJ, Herlevsen M, Harding MA, Gulding KM, Moskaluk CA, et al. (2004) PTEN can inhibit in vitro organotypic and in vivo orthotopic invasion of human bladder cancer cells even in the absence of its lipid phosphatase activity. Oncogene 23: 6788-6797.
9. Wu Y, McRoberts K, Berr SS, Frierson Jr HF, Conaway M, et al. (2007) Neuromedin U is regulated by the metastasis suppressor RhoGDI2 and is a novel promoter of tumor formation, lung metastasis and cancer cachexia. Oncogene 6: 765-773.
10. Sanchez-Carbayo M, Socci ND, Lozano JJ, Haab BB, Cordon-Cardo C, (2006) Profiling bladder cancer using targeted antibody arrays. Am J Pathol 168: 93-103.
11. Orenes-Piñero E, Barderas R, Rico D, Casal JI, Gonzalez-Pisano D, et al. (2010) Serum and tissue profiling in bladder cancer combining protein and tissue arrays. J Proteome Res. 9: 164-73.
12. Ong SE, Blagoev B, Kratchmarova I, Kristensen DB, Steen H, et al. (2002) Stable isotope labelling by amino acids in cell culture SILAC as a simple and accurare approach to expression proteomics. Mol Cell Proteomics 1: 376-386.
13. Luque-García JL, Martínez-Torrecuadrada JL, Epifano C, Cañamero M, Babel I, et al. (2010) Differential protein expression on the cell surface of colorectal cancer cells associated to tumor metastasis. Proteomics 10: 940-52.
14. Gronborg M, Kristiansen TZ, Iwahori A, Chang R, Reddy R, et al. (2006) Biomarker discovery from pancreatic cancer secretome using a differential proteomic approach. Mol. Cell. Proteomics 5: 157-171.
15. Everyley PA, Krijgsveld J, Zetter BR, Gygi SP, (2004) Quantitative cancer prpteomics: stable isotope labelling with amino acids in cell culture (SILAC) as a tool for prostate cancer research. Mol. Cell. Proteomics 3: 729-735.
16. Zhang G, Fenyo D, Neubert TA, (2008) Screening for EphB signalling effectors using SILAC with a linear ion trap-orbitrap mass spectrometer. J. Proteome Res 7: 4725-4726.
17. Dobreva I, Fielding A, Foster LJ, Dedhar S, (2008) Mapping the integrin-linked kinase interactome using SILAC. J. Proteome Res 7: 1740-1749.
18. Qiu H, Wang Y, (2008) Quantitative analysis of surface plasma membrane proteins of prmary and metastatic melanoma cells. J Proteome Res 7: 1904-1915.
19. Chen N, Sun W, Deng X, Hao Y, Chen X, et al. (2006) Quantitative proteome analysis of HCC cell lines with different metastatic potentials by SILAC. Proteomics 8: 5108-5118.
20. Pijnappel WP, Kolkman A, Baltissen MP, Heck AJ, Timmers HM, (2009) Quantitative mass spectrometry of TATA binding protein-containing complexes and subunit phosphorylations during the cell cycle. Proteome Sci. 7: 46.
21. Lam YW, Evans VC, Heesom KJ, Lamond AI, Matthews DA, (2010) Proteomics analysis of the nucleolus in adenovirus-infected cells Mol Cell Proteomics. 9: 117-130.
22. Rangiah K, Tippornwong M, Sangar V, Austin D, Tetreault MP, et al. (2009) Differential secreted proteome approach in murine model for candidate biomarker discovery in colon cancer. J Proteome Res 8: 5153-5164.
23. Zhang G, Spellman DS, Skolnik EY, Neubert TA, (2006) Quantitative phosphotyrosine proteomics of EphB2 signaling by stable isotope labelling by amino acids in cell culture (SILAC) J. Proteome Res. 5: 581-588.
24. Lund R, Leth-Larsen R, Jensen ON, Ditzel HJ, (2009) Efficient isolation and quantitative proteomic analysis of cancer cell plasma membrane proteins for identification of metastasis-associated cell surface markers. J Proteome Res 8: 3078-3090.
25. Ong SE, Mann M, (2006) A practical recipe for stable isotope labelling by amino acids in cell culture (SILAC) Nat Protoc. 1: 2650-2660.
26. Mann M, (2006) Functional and quantitative proteomics using SILAC. Nat. Rev. Mol Cell Biol 7: 952-958.
27. Guha U, Chaerkady R, Marimuthi A, Patterson AS, Kashyap MK, et al. (2008) Comparisons of tyrosine phosphorylated proteins in cells expressing lung cancer-specific alleles of EGFR and KRAS. Proc Natl Acad Sci USA 105: 14112-14117.
28. Sun Y, Mi W, Cai J, Ying W, Liu F, et al. (2008) Quantitative proteomic signature of liver cancer cells: tissue transglutaminase 2 could be a novel protein candidate of human hepatocellular carcinoma. J. Proteome Res 7: 3847-3859.
29. Pan C, Olsen JV, Daub H, Mann M, (2009) Global effects of kinase inhibitors on signalling networks revealed by quantitative phosphoproteomics. Mol Cell Proteomics 8: 2796-2808.
30. Spellman DS, Deinhardt K, Darie CC, Chao MV, Neubert TA, (2008) Stable isotopic labelling by amino acids in cultured primary neurons: application to brain-derived neurotrophic factor-dependent phosphotyrosine-associated signalling. Mol. Cell. Proteomics 7: 1067-1076.
31. Selbach M, Schwanhäusser B, Thierfelder N, Fang Z, Khanin R, et al. (2008) Widespread changes in protein synthesis induced by microRNAs. Nature 455: 58-63.
32. Sánchez-Carbayo M, Socci ND, Charytonowicz E, Lu M, Prystowsky M, et al. (2002) Molecular profiling of bladder cancer using cDNA microarrays: defining histogenesis and biological phenotypes. Cancer Res 62: 6973-6980.
33. Ruppen I, Grau L, Orenes-Piñero E, Ashman K,et al. Differential protein expression profiling by iTRAQ-two-dimensional LC-MS/MS of human bladder cancer EJ138 cells transfected with the metastasis suppressor KiSS-1 gene. Mol Cell Proteomics. 9: 2276-91.
34. Sanchez-Carbayo M, Socci ND, Lozano J, Saint F, Cordon-Cardo C, (2006) Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays. J Clin Oncol 24: 778-89.
35. American Joint Committee on Cancer: Staging of cancer at genitourinary sites (1988) In:American Joint Committee on Cancer: Manual for Staging of Cancer, 3rd Edition. Philadelphia: J. B., Lippincott, Co. 194-195.
36. Dawson-Saunders B, Trapp RG (1994) Basic & Clinical Biostatistics. 2nd edition, Norwalk, Connecticut, Appleton & Lange.
37. Du M, Sansores-Garcia L, Zu Z, Wu KK, (1998) Cloning and expression analysis of a novel salicylate suppressible gene, Hs-CUL-3, a member of cullin/Cdc53 family. J Biol Chem 273: 24289-24292.
38. Furukawa M, He YJ, Borchers C, Xiong Y, (2003) Targeting of protein ubiquitination by BTB-Cullin 3-Roc1 ubiquitin ligases. Nature Cell Biol 5: 1001-1007.
39. Petroski MD, Deshaies RJ, (2005) Function and regulation of cullin-RING ubiquitin ligases. Nature Rev. Mol. Cell Biol 6: 9-20.
40. Van den Heuvel S, (2004) Protein degradation: CUL-3 and BTB - partners in proteolysis. Curr Biol 14: R59-R61.
41. Singer JD, Gurian-West M, Clurman B, Roberts JM, (1999) Cullin-3 targets cyclin E for ubiquitination and controls S phase in mammalian cells. Genes Dev 13: 2375-2387.
42. Wilkins A, Ping Q, Carpenter CL, (2004) RhoBTB2 is a substrate of the mammalian CUL-3 ubiquitin ligase complex. Genes Dev 18: 856-61.
43. Lee DF, Kuo HP, Liu M, Chou CK, Xia W, et al. (2009) KEAP1 E3 ligase-mediated downregulation of NF-kappaB signaling by targeting IKKbeta. Mol Cell 36: 131-40.
44. Pintard L, Willis JH, Willems A, Johnson JL, Srayko M, et al. (2003) The BTB protein MEL-26 is a substrate-specific adaptor of the CUL-3 ubiquitin-ligase. Nature 425: 311-316.
45. Hori T, Osaka F, Chiba T, Miyamoto C, Okabayashi K, et al. (1999) Covalent modification of all members of human cullin family proteins by NEDD8. Oncogene 18: 6829-6834.
46. Wu JT, Lin HC, Hu YC, Chien CT, (2005) Neddylation and deneddylation regulate CUL1 and cul-3 protein accumulation. Nat Cell Biol 7: 1014-1020.
47. Soucy TA, Smith PG, Milhollen MA, Berger AJ, Gavin JM, et al. (2009) An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer. Nature 458: 732-736.
48. Mani A, Gelmann EP, (2005) The ubiquitin-proteasome pathway and its role in cancer. J. Clin Oncol. 23: 4776-4789.
49. Sanchez-Carbayo M, Socci ND, Richstone L, Corton M, Behrendt N, et al. (2007) Genomic and proteomic profiles reveal the association of gelsolin to TP53 status and bladder cancer progression. Am J Pathol 171: 1650-8.
50. Palou J, Algaba F, Vera I, Rodriguez O, Villavicencio H, et al. (2009) Protein Expression Patterns of Ezrin Are Predictors of Progression in T1G3 Bladder Tumours Treated with Nonmaintenance Bacillus Calmette-Guérin. Eur Urol. 56: 829-836.